Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$166.1KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dwight Egan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 115
- Beta
- 2.85
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.48
Financials
Revenue
$166.1K+6636.9%Net Income
$-6.28MEBITDA
$-5.92MFree Cash Flow
$-7.17MEPS (diluted)
$-1.46Shares Outstanding (diluted)
4.31M+1056.3%Operating Expenses
$6.12MCash & Debt
$3.65MReturn of Capital
$0.00Revenue by Segment (annual)
$622.5KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $622.5K | $-46.90M | $-35.25 |
| 2024 | $3.92M | $-37.64M | $-37.20 |
| 2023 | $6.81M | $-35.33M | $-36.00 |
| 2022 | $34.22M | $-14.24M | $-13.57 |
| 2021 | $97.89M | $36.66M | $38.10 |
| 2020 | $74.55M | $42.48M | $1.59 |
| 2019 | $215.0K | $-6.20M | $-11.09 |
| 2018 | $39.9K | $-6.27M | $-15.00 |
| 2017 | $7.7K | $-6.96M | $-18.90 |
| 2016 | $0.00 | $-1.93M | $-5.10 |
| 2015 | $10.0K | $-2.04M | $-5.40 |
| 2014 | $0.00 | $-1.05M | $-3.90 |
Valuation
CODXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
145+107.14%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·19d ago·Positive
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
View source ↗ - Newsprnewswire.com·20d ago·Negative
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients Company to hold in-person pres
View source ↗ - Newsprnewswire.com·20d ago·Neutral
Co-Diagnostics to Hold Press Conference Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m.
View source ↗ - Newsprnewswire.com·33d ago·Neutral
…studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of its integrated cloud infrastructure in India.
View source ↗ - Newsprnewswire.com·49d ago·Neutral
…in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, h…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-1.25 per share
Typical surprise +8.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.46 vs $-3.00beat
- Thu, May 14$-4.06 vs $-3.75miss
- Tue, Mar 31$-16.35 vs $-3.60miss
- Thu, Nov 13$-4.80 vs $-5.71beat
- Thu, Aug 14$-6.91 vs $-7.51beat
- Thu, May 8$-7.21 vs $-8.10beat
Estimates and results for CODX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CODX officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CODX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.